Britain said on Friday it had signed a deal for the supply of up to 90 million doses of potential Covid-19 vaccines under development.
New in-principle agreements were made with Novavax, a U.S. vaccine development company, and Belgium’s Janssen Pharmaceutical Companies that is part of Johnson and Johnson, the government said.
Novavax is to provide 60 million doses, while 30 million doses will be secured from Janssen.
Britian – a country of 66.6 million – has following Friday’s announcement secured early access to about 340 million vaccine doses.
They were from six different candidates, across four different vaccine types.
“The government’s strategy to build a portfolio of promising vaccine candidates will ensure we have the best chance possible of finding one that works,” Business Secretary Alok Sharma said in a statement.
Novavax plans to manufacture some of the vaccine in Britain at Billingham, Stockton-on-Tees.